Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model

Publish Year: 1391
نوع سند: مقاله ژورنالی
زبان: English
View: 139

This Paper With 14 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-15-5_006

تاریخ نمایه سازی: 4 آبان 1400

Abstract:

Objective(s)CpG oligodeoxynucleotides (CpG ODNs) have been shown to have potent immunostimulatory adjuvant activity for a wide range of antigens. Due to susceptibility of phosphodiester CpG ODNs (PO CpG) to nuclease degradation, nuclease-resistant phosphorothioate CpG ODNs (PS CpG) were currently utilized in an in vivo model. In this study, according to some recently reported drawbacks with PS CpG, the adjuvant potential of liposomal PO CpG as a substitute for PS CpG was evaluated.Materials and MethodsSoluble Leishmania antigens (SLA) as a model antigen and distearoylphosphatidylcoline (DSPC) as a neutral lipid were employed to prepare liposomes. Susceptible BALB/c mice received buffer, SLA, Lip-SLA, Lip-SLA-PS CpG, Lip-SLA-PO CpG, SLA+PS CpG, or SLA+PO CpG subcutaneously ۳ times with ۳ weeks intervals and then were challenged with Leishmania major’s live promastigotes. Blood and spleen samples were analyzed to determine the level and type of antibodies and cytokines. The number of live parasites in the spleen of immunized mice was determined. Moreover, the lesion size progress was assessed weekly by footpad swelling measurement.ResultsThe results showed that mice immunized with Lip-SLA-PS CpG or Lip-SLA-PO CpG developed a significantly smaller footpad swelling, higher level of anti SLA IgG antibodies before and after challenge, and lower spleen parasite burden compared with the control groups. However, there was no significant difference between mice received Lip-SLA-PS CpG and those received Lip-SLA-PO CpG.ConclusionThe results demonstrated that liposomal PO CpG ODN could be used instead of PS CpG ODN to overcome the possible drawbacks.

Authors

Ensieh Golali

Nanotechnology Research Centre, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Mahmoud Reza Jaafari

Nanotechnology Research Centre, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Khamesipour

Centre for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Azam Abbasi

Nanotechnology Research Centre, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Zahra Saberi

Nanotechnology Research Centre, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Badiee

Nanotechnology Research Centre, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Krieg AM. CpG motifs in bacterial DNA and their immune ...
  • Klinman DM, Currie D, Gursel I, Verthelyi D. Use of ...
  • Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, ...
  • Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis ...
  • Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, ...
  • Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, ...
  • Levin AA. A review of the issues in the pharmacokinetics ...
  • Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of ...
  • Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, ...
  • Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, ...
  • Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense ...
  • Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. ...
  • Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, ...
  • Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, ...
  • Kim D, Rhee JW, Kwon S, Sohn WJ, Lee Y, ...
  • Kindrachuk J, Potter JE, Brownlie R, Ficzycz AD, Griebel PJ, ...
  • Haas T, Metzger J, Schmitz F, Heit A, Muller T, ...
  • Yasuda K, Rutz M, Schlatter B, Metzger J, Luppa PB, ...
  • Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert ...
  • Semple SC, Klimuk SK, Harasym TO, Hope MJ. Lipid-based formulations ...
  • Wilson KD, de Jong SD, Tam YK. Lipid-based delivery of ...
  • Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. ...
  • Alving CR. Liposomal vaccines: clinical status and immunological presentation for ...
  • O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery ...
  • Copland MJ, Rades T, Davies NM, Baird MA. Lipid based ...
  • Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, ...
  • Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler ...
  • Muller I, Kropf P, Louis JA, Milon G. Expansion of ...
  • Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, ...
  • Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, ...
  • Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib ...
  • Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. ...
  • Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, ...
  • Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, ...
  • Manuel S, Laura R, rez, Miguel AP, Victor MG, lez, ...
  • Badiee A, Jaafari MR, Samiei A, Soroush D, Khamesipour A. ...
  • Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, ...
  • Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, ...
  • Scott P, Pearce E, Natovitz P, Sher A. Vaccination against ...
  • Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. ...
  • Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL. CpG ...
  • Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response ...
  • Taswell C. Limiting dilution assays for the determination of immunocompetent ...
  • Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, ...
  • Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are ...
  • Sun S, Zhang X, Tough DF, Sprent J. Type I ...
  • Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine ...
  • Yi AK, Chace JH, Cowdery JS, Krieg AM. IFN-gamma promotes ...
  • Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur ...
  • Shi F, Hoekstra D. Effective intracellular delivery of oligonucleotides in ...
  • Rao M, Alving CR. Delivery of lipids and liposomal proteins ...
  • Klinman DM, Currie D, Gursel I, Verthelyi D. Use of ...
  • Jiao X, Wang RY-H, Qiu Q, Alter HJ, Shih JW-K. ...
  • Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, ...
  • Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, ...
  • Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, ...
  • Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, ...
  • Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, ...
  • Rhee EG, Mendez S, Shah JA, Wu C-y, Kirman JR, ...
  • Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, ...
  • Mazumdar T, Anam K, Ali N. Influence of phospholipid composition ...
  • Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, ...
  • Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, ...
  • Jiao X, Wang RYH, Feng Z, Alter HJ, Shih JWK. ...
  • Heravi Shargh V, Jaafari MR, Khamesipour A, Jalali SA, Firouzmand ...
  • McConville MJ, Thomas-Oates JE, Ferguson MA, Homans SW. Structure of ...
  • Souto-Padron T. The surface charge of trypanosomatids. An Acad Bras ...
  • نمایش کامل مراجع